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Objective: The optimal treatment of pediatric empyema remains controversial. The
objective of this study is to compare the use of conventional management versus
primary thoracoscopic drainage and decortication in children with empyema.
Methods: Conventional management has consisted of chest drain insertion under
general anesthesia plus intravenous antibiotics. Thoracoscopic drainage and decor-
tication has consisted of primary thoracoscopic drainage and decortication plus
antibiotics. The clinical course of 54 patients treated conventionally between 1989
and 1997 was compared with that of 21 patients treated by means of thoracoscopic
drainage and decortication between September 2000 and September 2001.
Results: Results of the study demonstrated that patients in the drainage-decortication
group had fewer invasive interventions per patient than those in the conventional
management group (1.0 vs 1.26). Patients undergoing thoracoscopic drainage and
decortication also had significantly shorter durations of intravenous antibiotic ther-
apy (7.6  1.2 vs 18.2  7.5 days), chest tube drainage (4.0  0.5 vs 10.2  6.1
days), and hospital stays (7.4  0.8 vs 15.4  7.4). Moreover, there were no open
thoracotomies and decortications in the thoracoscopic drainage and decortication
group, whereas in the conventional management group 39% (21/54) of patients
underwent an open procedure.
Conclusion: Although the 2 groups were not prospectively randomized and they
were treated in different time periods, the results of this study support the use of
thoracoscopic surgery as the primary therapeutic modality in children presenting
with pleural empyema. This strategy appears to offer significant benefits over
conventional treatment in terms of duration of treatment and the need for more
invasive surgery.
Approximately 0.6% of childhood cases of pneumonia are compli-cated by the formation of pleural empyema. The incidence ofempyema ranges from 0.4 to 6 per 1000 pediatric admissions.Despite this condition being relatively common, the managementof empyema in children remains controversial.1
The American Thoracic Society has classified empyema as having 3 fairly
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distinct phases: an early exudative or pre-empyema phase
(stage 1), an intermediate fibrinopurulent phase (stage 2),
and a late organizing or chronic phase (stage 3).2 Stage 1
empyema is usually characterized by a nonlocular para-
pneumonic effusion with fibrin deposited over all surfaces
but not thick enough to prevent the lung from re-expanding
when the fluid is drained. Stage 2 empyema demonstrates
heavy fibrin deposits over all of the pleural surfaces, and
some degree of lung trapping occurs. The fluid (if present)
is usually grossly purulent and might have positive bacterial
cultures. Stage 3 empyema is characterized by a thick fi-
brotic peel, and the lung cannot re-expand, even in the face
of an emptied pleural space.
In the earliest stages pleural empyema is treated by
means of chest tube drainage as an adjunct to intravenous
antibiotic therapy. Progression of the empyema with the
development of fibrinous adhesions and loculations makes
simple drainage difficult if not impossible.2 Chest tube
drainage and intravenous antibiotic therapy might be ade-
quate for stage 1 empyema. However, this approach is
rarely effective in patients with stage 2 or 3 disease. Al-
though there might be clinical improvement with drainage
of the pleural space and antibiotic therapy, re-expansion of
the entrapped lung is unlikely to occur in a significant
number of cases, and this ultimately leads to surgical inter-
vention.
Recognizing the limitations to this approach, some re-
searchers have advocated the use of intrapleural fibrinolytic
agents as a form of chemical debridement to enhance pleu-
ral drainage and to disrupt loculations. There have been 3
randomized controlled trials with intrapleural administra-
tion of fibrinolytic substances in adult patients.3-5 Most
recently, the first multicenter randomized trial of intrapleu-
ral urokinase in pediatric patients has been reported from
the United Kingdom.6
Despite recent treatment advances in the management of
pediatric empyema, there is still a significant failure rate,
leading to long hospital stays and open thoracotomy. In our
institution children receive a general anesthetic for place-
ment of a chest drain. This is done for the physical and
mental well-being of the patient. As such, we reasoned that
because the patient was already under anesthesia and in the
theater, a slightly more aggressive and thorough treatment
of the empyema with thoracoscopy could ultimately be of
benefit to the patient. The purpose of the present study was
to determine whether early primary intervention with tho-
racoscopic drainage and decortication (TDD) in pediatric
patients had any clinical benefit over conventional treatment
(chest tube drainage, antibiotics, and observation with open
thoracotomy being reserved for patients for whom medical
management fails).
Methods
The study is a retrospective analysis of patients referred or admit-
ted to Great Ormond Street Hospital for Children (London, United
Kingdom) with a diagnosis of pleural empyema. The diagnosis but
not the staging of empyema was based on clinical and radiographic
criteria. The conventional management (CM) group consisted of
all patients admitted with this diagnosis between January 1989 and
April 1997. Patients in the CM group underwent conventional
treatment, which consisted of initial therapy with chest tube and
antibiotics alone.7 The policy in our institution is to place all chest
drains in the operating theater under general anesthesia for the
physical and mental comfort of the child.
Between September 2000 and September 2001, 27 consecutive
patients underwent thoracoscopic treatment of the disease. In 6 of
27 patients, a chest drain had been inserted at the referring hospi-
tal, and this was considered the primary intervention. Because the
purpose of this study was to evaluate the benefit of primary TDD
of pleural empyema, only those patients without a previous inter-
vention were considered for this study. There were a total of 54
patients in the CM group versus a total of 21 patients in the TDD
group.
Patients in the CM group all underwent chest radiography, and
some had the addition of a chest ultrasound scan, a chest computed
tomographic scan, or both. All patients in the TDD group had a
computed tomographic scan of the chest before the operation and
were taken to the operating theater within 24 hours of admission.
Video-assisted thoracoscopic surgical interventions and thora-
cotomy were performed in the operating theater under general
anesthesia, with the patient in the decubitus position. On the basis
of the child’s size, either dual-lung or single-lung ventilation was
performed. TDD was performed with 5-mm instruments and in-
termittent carbon dioxide insufflation when necessary. Usually, 2
or 3 incisions were made, with one used to place a reusable trocar
for the camera and the second or third for grasping instruments. All
trocar sites were used interchangeably. Loculations were drained
during thoracoscopic visualization. Adherent lung was separated
from the parietal pleura, including the diaphragm and apex of the
chest cavity. The pleural debris was removed with the endoscopic
grasping device or by means of extensive irrigation and suctioning.
Either 1 or 2 chest drains were left behind, which were placed
through 1 or 2 of the port site incisions. Postoperative chest
radiography confirmed the position of the tube or tubes. Chest
tubes were removed when less than 1 mL/h fluid had drained over
a 24-hour period (ie, 24 mL/d).
The medical records were retrospectively reviewed for infor-
mation regarding demographics, side of empyema, duration and
mode of prehospital treatment, bacteriology, type and timing of
invasive procedures, and hospital course. Hospital course data
included total number of invasive procedures done, total number of
anesthetics, number of hospital days after intervention, postproce-
dure days, details of the operative course, number and duration of
chest tubes, and length of stay.
TABLE 1. Patient demographics
CM group TDD group
No. of patients 54 21
Male/female ratio 1.2:1 2:1
Age, mean  SEM (mo) 70.8 46.8 70.7 14.6
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Data collected were entered into a computerized statistical
program. Univariate statistical analysis was performed with the
Student t test. Data are expressed as the statistical average SEM.
A P value of less than .05 was considered significant.
Results
All patients admitted or referred to Great Ormond Street
Hospital and treated for empyema during the 2 time periods
were considered in this review. There were 54 admissions or
referrals for empyema during the period from January 1989
through April 1997 (CM group). Of the 27 admissions or
referrals for empyema between September 2000 and Sep-
tember 2001, 21 patients could be considered for primary
TDD (TDD group). All patients in the TDD group were
found to have stage 2 empyema at the time of the operation.
The demographics of the 2 groups are shown in Table 1.
There was a male/female ratio of 1.2:1 in the CM group,
whereas the ratio was 2:1 in the TDD group. The mean age
in the CM group was 70.8  46.8 months, whereas the
mean age in the TDD group was 70.7 14.6 months. Table
2 describes the characteristics of the empyemas in the 2
groups. In the CM group there were 23 (42.5%) left-sided
empyemas, 31 (57.5%) right-sided empyemas, and no bi-
lateral empyemas. In the TDD group there were 9 (42.9%)
left-sided empyemas, 10 (47.6%) right-sided empyemas,
and 2 (9.5%) bilateral empyemas. Pleural fluid cultures
were positive in 17 (31%) of 54 of the patients in the CM
group, with the most common organism isolated being
Staphylococcus aureus (7/17 [41%]). In the TDD group
there were 12 (57%) of 21 patients with a positive pleural
fluid culture, with the most common organism being Strep-
tococcus pneumoniae (4/12 [33%]).
Table 3 provides data on the invasive interventions of the
2 groups. In the CM group 47 (87%) of the 54 patients had
a chest drain inserted as the primary invasive intervention.
There were no patients in the TDD group who had a chest
drain as the primary invasive intervention. In the CM group
medical management failed in 21 (39%) of the 54 patients,
and thus these patients required an open thoracotomy and
decortication. No patients in the TDD group required open
thoracotomy. As a result of this, patients in the CM group
had an average of 1.26 invasive interventions per patient,
whereas patients in the TDD group had just 1.0 invasive
interventions per patient. Because all chest drains at our
institution are placed under a general anesthetic in the
operating theater, this also translates into 1.26 versus 1.0
administrations of general anesthesia and operating theater
uses per patient as well.
Compared with the CM group, the TDD group patients
had a significantly shorter duration of intravenous antibiotic
therapy (18.2  7.5 vs 7.6  1.2 days, P  .001), chest
tubes in situ (10.2  6.1 vs 4.0  0.5 days, P .001), and
hospital stays (15.4  7.4 vs 7.4  0.8 days, P  .001), as
shown in Figure 1.
There were no recurrences of empyema in either group
once the patient was discharged from the hospital.
Discussion
In 1918, Graham and Bell8 described the basic principles
of empyema management: complete drainage of the puru-
lent collection, obliteration of the empyema space, and
treatment of the underlying infection. In practice these prin-
ciples have largely translated into percutaneous chest tube
drainage and antibiotic therapy. Unfortunately, this practice
has been uniformly associated with prolonged hospital stays
and a high incidence of open thoracotomy and decortication
in patients who were left with trapped lung and a residual air
space.
The aim of treatment is to sterilize the pleural cavity and
ensure full re-expansion of the lung. Chest tube drainage
and intravenous antibiotic therapy might be adequate for
stage 1 empyema. However, this approach is rarely effective
in patients with stage 2 or 3 disease. Although there might
be clinical improvement with drainage of the pleural space
and antibiotic therapy, re-expansion of the entrapped lung is
less likely to occur, and this leads to surgical intervention in
a significant number of cases. Recognizing this, attempts to
improve medical management have been tried for over 50
years.
As early as 1949, Tillet and Sherry9 reported the use of
streptococcal fibrinolysin and streptococcal deoxyribonu-
clease as lytic agents in the treatment of fibrinous, purulent,
and sanguineous pleural exudations. These early attempts at
lytic therapy were ultimately abandoned because the early
preparations lacked purity, and antibiotics and surgical tech-
TABLE 2. Empyema characteristics
CM group TDD group
Left-sided empyema 23 (42.5%) 9 (42.8%)
Right-sided empyema 31 (57.5%) 10 (47.6%)
Bilateral empyema 0 2 (9.5%)
Positive pleural cultures 17/54 (31%) 12/21 (57%)
Most common organism
cultured
Staph aureus
7/17 (41%)
Strep pneum.
4/12 (33%)
TABLE 3. Invasive interventions
CM group TDD group
Primary chest drain 47/54 (87%) 0
VATS 0 21/21 (100%)
Thoracotomy 21/54 (39%) 0
Procedures per patient 1.26 1.0
Results are translated into the average number of procedures per patient
in each group. VATS, Video-assisted thoracoscopic surgery.
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niques improved.10 Since then, fibrinolytic agents have been
reported anecdotally in adult and pediatric patients.
Attempts at improving surgical management have also
evolved in the treatment of empyema. In 1985, Hutter and
colleagues11 described a protocol of treating adult patients
with empyema with the use of thoracoscopy and irrigation.
Since then, technical advances in equipment have made
thoracoscopy a readily available tool to the thoracic sur-
geon. As a result, thoracoscopy has been applied to the
treatment of empyema in both adult and pediatric patients.
Beginning in the 1990s, reports describing the use of tho-
racoscopy for the treatment of empyema in children began
to surface.12,13
In the current era there has been a renewed interest in
more aggressive medical management of empyema in an
attempt to avoid long hospital stays and surgical interven-
tions. Recently, the first multicenter randomized trial of
intrapleural urokinase in pediatric patients was conducted in
the United Kingdom.6 The results of this study have led to
a change in practice among many of the centers in the
United Kingdom. In this study there was an approximately
10% failure of medical management, which led to open
thoracotomy. Unfortunately, the results of this study might
not be representative of the typical cases of pediatric em-
pyema seen in most centers. The data from this multicenter
trial demonstrated that at least one half of the patients
treated were found to have clear fluid, and one third of the
patients had nonloculated effusions. Thus it could be argued
that by any staging criteria, these patients did not truly
qualify as having stage 2 disease. As a result, these patients
would have been less likely to have had unsuccessful con-
ventional therapy and to progress to requiring more invasive
treatment (ie, thoracotomy).
In contrast to the approach used by Thompson and co-
workers,6 we used thoracoscopy as the primary modality of
treatment. In our series all patients had at least stage 2
empyema on the basis of radiographic criteria, and this was
confirmed at the time of thoracoscopy. Our results suggest
that this is an efficacious strategy for the management of
pediatric empyema. We recognize that patients with clear
fluid and a parapneumonic effusion (stage 1) could benefit
from conventional medical treatment alone with simple
drainage of the pleural space and antibiotics. However,
because of the referral patterns of the patients that we see,
no patients with stage 1 empyema were admitted during the
period in which we used a primary thoracoscopic approach.
The strategy of using thoracoscopy as the primary mo-
dality of treatment has recently been reported, although with
some differences. In 2000, Doski and coworkers14 reported
their experience with 139 pediatric patients with empyema
referred for surgical therapy. In one of their 3 groups, 41
patients underwent primary video-assisted thoracoscopic
surgery over a 6-year period. Similar to our study, they
demonstrated a clinical benefit to patients undergoing pri-
mary thoracoscopic treatment. Their study differs from ours
in that they only saw patients who were referred for surgical
therapy. Our protocol called for all patients admitted or
referred to the hospital during the 12-month period to un-
dergo primary TDD.
The results of our study demonstrated a clear clinical
benefit to patients undergoing primary TDD when com-
pared with conventional therapy in the same institution.
Overall, patients in the TDD group experienced signifi-
cantly shorter hospital stays, fewer invasive procedures, and
shorter duration of intravenous antibiotic therapy and chest
tube drainage. Most significantly, the number of thoracoto-
Figure 1. Clinical durations of intravenous antibiotic therapy, chest tube drainage, and hospital stay expressed as
averages  SEM.
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mies that patients underwent in the CM group relative to
those in the TDD group was dramatic.
In summary, the current study focuses on a specific
subgroup of pediatric patients with stage 2 empyema who
have undergone TDD as a primary invasive intervention.
The study attempts to demonstrate that this type of approach
to the treatment of empyema might have significant benefits
when compared with medical management.
There are, however, limitations to this study. It is a
retrospective, nonrandomized, observational study of 2
groups of patients treated in different time periods. Drawing
overly strong conclusions on the basis of these limitations
would be inappropriate. Despite this, there does appear to be
a clinical benefit to treating all patients with primary TDD.
In the current era medical specialists are increasingly using
intrapleural fibrinolytic agents as an adjunct to conventional
therapy. We believe that a prospective randomized trial of
conventional therapy plus intrapleural fibrinolytic agents
should be compared with primary thoracoscopic treatment
of stage 2 or 3 empyema in the pediatric population. Such a
study is already underway. The hope is that this will enable
practitioners to identify which patients would most likely
benefit from each of the 2 therapeutic modalities in an effort
to develop a standardized protocol for the treatment of
pediatric empyema.
In conclusion, initial results from this review would
suggest that in the current era there might be an overall
clinical benefit from treating pediatric patients with empy-
ema with a primary thoracoscopic intervention rather than
with conventional therapy with primary chest drainage only.
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Discussion
Dr D. Wood (Seattle, Wash). First of all, I appreciate being
allowed to be in the congenital session. I had many people ask me
whether I was in the right place as I walked in, but I assured them
that I was not going to be discussing an arterial switch paper. I do
feel that I could talk about empyema, unfortunately, having dealt
with it a fair bit.
I would like to offer my congratulations to Dr Cohen and his
colleagues at Great Ormond Street for an elegantly presented
article that improves our knowledge of how to care for children
with pleural empyema. Dr Cohen rightly points out the obvious
limitations of an observational study that evaluates 2 different
treatment strategies over 2 different time periods, but this should
not dissuade us from appreciating the benefit of thoracoscopic
debridement, that is, a decreased duration of antibiotics, chest tube
duration, and hospital stay.
However, I do not accept the apparent decrease in invasive
interventions in the latter group. Although 39% of the patients
receiving chest tubes required further intervention (ie, a thoracot-
omy), 61% required a chest tube as the solo intervention, and that
is clearly less invasive than the thoracoscopy that all patients
received in the second time period. On a scale of invasiveness, one
might actually claim that patients had fewer major interventions
before the institution of thoracoscopy.
To me, it seems rather artificial that no one in the first group
underwent a thoracoscopy before thoracotomy and likewise that no
one in the second group had a chest tube drainage before thora-
coscopy, although this was the definition of the group selected.
I agree with your conclusion that early aggressive management
minimizes morbidity and hospitalization. However, an algorithm
of progressively invasive procedures, promptly applied and eval-
uated, provides the ability to minimize invasive procedures and
empyema morbidity. An efficient strategy would start with chest
tube placement unless the history and imaging made it clear that
this would be futile. A chest computed tomographic scan should
then follow within 12 to 24 hours, and if complete evacuation and
lung expansion is not accomplished, the patient should go on to a
thoracoscopy. If complete lung expansion is not achieved by
means of thoracoscopy, a more formal thoracotomy and decorti-
cation can be performed at the same operation. In this algorithm a
definitive resolution will be accomplished within 24 to 48 hours,
but some patients will also be successfully treated with tube
thoracostomy alone and be able to avoid even a thoracoscopy.
Dr Cohen, why did you make such a radical treatment change
in September 2000? Do you believe a short trial of chest tube
drainage precludes successful thoracoscopic decortication? What
clinical and radiologic characteristics do you use to decide to
proceed directly to surgical intervention?
Cohen et al General Thoracic Surgery
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I am delighted to see your plans for a randomized trial com-
paring fibrinolytics with thoracoscopy. My bias is that the results
will direct pediatricians to involve the thoracic surgeons early in
the course of empyema management to the ultimate benefit of the
patient. I applaud your fine work and your elegant presentation.
Thank you for the privilege of the discussion.
Dr Cohen. Thank you, Dr Wood, for your comments and for
taking time out from the session you are chairing to discuss our
article.
I think that your comments about chest tube drainage as an
initial invasive intervention and, giving that a chance, then fol-
lowed by thoracoscopy are appropriate. However, in the pediatric
population, all these invasive interventions are done under general
anesthesia. Therefore, not only are we exposing the patients to a
procedure in and of itself, but we are also exposing them to general
anesthesia, which requires endotracheal intubation and recovery
from each of the procedures.
Even the procedure of just having a thoracentesis for obtaining
the fluid involves sedation; therefore, to undergo the protocol that
you would propose in this situation, a child would have an initial
sedation with a thoracentesis, followed by general anesthesia for
placement of a chest drain, followed by general anesthesia for the
thoracoscopy. Therefore, we found that we have used this aggres-
sive and radical approach, as you might call it, to do everything at
once. We take the patients as they come through the door, and, at
the time they are given the first course of general anesthesia, we
are able to accomplish all 3 things at once. I think we found that
the invasiveness of the procedure has been greatly reduced as a
result, and the patients get the one isolated intervention.
There is another benefit, and we might disagree on this. You
say 61% of the patients were successfully treated with chest tube
drainage alone, but conversely, it would require yet an additional
period of general anesthesia for those patients to undergo a thora-
cotomy. Therefore, I believe that this approach eliminates a lot of
these extra steps and gets right to the heart of treating the disease
from the outset.
The second thing is that a double-blind, randomized, prospec-
tive, multicenter trial conducted in the United Kingdom was just
recently published, looking at chest tube drainage with and without
the use of intrapleural urokinase. I do not want to spend time
discussing that study in detail, but they showed a slight benefit in
terms of overall hospital stay if the patients received intrapleural
urokinase.
That article, since being published, has caused a change in
terms of the practice of the treatment of empyema in the United
Kingdom. Unfortunately, I have been getting a number of patients
in whom urokinase therapy has failed. The process of doing the
decortication after the patient has received urokinase is made
infinitely more difficult as a result of the change in the character-
istics of the peel itself; it becomes much stickier and much more
difficult to remove. In fact, of now greater than 50 patients who
have undergone thoracoscopic treatment of empyema, the only
patient who was ever converted to an open thoracotomy was a
patient in whom urokinase therapy had failed.
The majority of patients we have seen have not undergone
primary therapy with thoracoscopy, and a large group of patients
had a chest drain in place before transfer. Those patients were
excluded from this group because they were not treated primarily
with thoracoscopy. However, in terms of the time of treatment,
from the time we intervened when they arrived at our hospital and
performed the thoracoscopy, the data are very similar to the data
that I have just shown you.
Finally, in terms of the time line of our treatment regimen in
addressing why we went into this specific protocol, in May 2000,
we did our first thoracoscopic treatment primarily of empyema.
But between May 2000 and September 2000, patients were just
randomly treated with no specific protocol. They either received
conventional therapy or thoracoscopic treatment, and there was no
specific manner in which it was taken.
Then we decided in September 2000 to implement a policy of
taking every patient that came into the hospital with empyema and
treating them only thoracoscopically. During that period, there
were 27 patients who were admitted, but 6 of those patients had a
chest tube already in place at the time of transfer and, therefore,
only 21 of those patients could be considered for primary thora-
coscopic treatment.
At the conclusion of this, and this is also in relationship to the
article that was just recently published on the use of intrapleural
fibrinolytics, we decided to embark on a randomized prospective
trial to determine which was better, primary thoracoscopy or chest
drain with intrapleural fibrinolytics. Therefore, between September
2001 and the present, patients have been randomized to each of
these 2 groups.
Dr A. Laudito (Jackson, Miss). I want to congratulate you for
the data that you presented, but I believe we are arguing between
2 alternatives that are part of our armamentarium to treat this
problem. First, if you are having fresh empyemas, the thoraco-
scopic approach is very successful, as you brilliantly described.
However, in old organized empyemas, your results are not going to
be so successful, like a minithoracotomy, where you can directly
remove a difficult peel. Second, I do not know how many of the
present pediatric cardiac surgeons request general anesthesia to
place a chest tube in a neonate, in infants, or in pediatric patients.
Dr Cohen. I appreciate your comments. I think that the reason
for the general anesthesia is not for the surgeon but rather for
patient comfort, and it is a general protocol in our hospital for all
pediatric patients. It has nothing to do with what the surgeon needs
or does not need.
(Slide) In terms of the result that we get, this slide shows that
same patient on postoperative day 3, and I think the result actually
is very good. I am not sure that a much better result can be
obtained by waiting for the peel to mature and then stripping the
peel off through a thoracotomy. In fact, we have done it thoraco-
scopically, and it is much more difficult to do, although it can be
done.
Dr Laudito. My point is that according to the stage of empy-
ema, you can apply a different treatment.
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